Acurx Pharmaceuticals Secures Patent For DNA Polymerase IIIC

On February 2, Acurx Pharmaceuticals announced the USPTO granted patent US 12,534,470 covering DNA Polymerase IIIC inhibitors, including compositions, methods, and pharmaceutical formulations for its ACX-375C program. The grant expands Acurx's IP portfolio—now four U.S. patents plus international grants—and underpins its AI-supported drug discovery platform. The company cites preclinical microbiome-selective data and a pipeline including Phase‑3-ready ibezapolstat and candidates for MRSA, pneumonia, bacteremia, and anthrax.